Status: Not yet recruiting
A Study to Evaluate the Safety and Efficacy of NT-88
A study to evaluate the safety and preliminary efficacy of Zuozhu Daxi in patients with chronic heart failure with mildly reduced ejection fraction
Participants needed: 60
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Guangzhou Manjing biomedicine technology co., ltdUpdated: Apr 3, 2026
Eligibility criteria
Aged ≥18 years, no gender restriction; [+6]
Known allergy to any component of the investigational product; [+15]